Abstract:Background Tumor DNA has been shown to be present both in circulating tumor cells in blood and as fragments in the plasma of metastatic cancer patients. The identification of ultra-rare tumor-specific mutations in blood would be the ultimate marker to measure efficacy of cancer therapy and/ or early recurrence. Herein we present a method for detecting microinsertions/deletions/indels (MIDIs) at ultra-high analytical selectivity. MIDIs comprise about 15% of mutations. Methods and Findings We describe MIDI-Activated Pyrophosphorolysis (MAP), a method of ultra-high analytical selectivity for detecting MIDIs. The high analytical selectivity of MAP is putatively due to serial coupling of two rare events: heteroduplex slippage and mis-pyrophosphorolysis. MAP generally has an analytical selectivity of one mutant molecule per >1 billion wild type molecules and an analytical sensitivity of one mutant molecule per reaction. The analytical selectivity of MAP is about 100,000-fold better than that of our previously described method of Pyrophosphorolysis Activated Polymerization-Allele specific amplification (PAP-A) for detecting MIDIs. The utility of this method is illustrated in two ways. 1) We demonstrate that two EGFR deletions commonly found in lung cancers are not present in tissue from four normal human lungs (107 copies of gDNA each) or in blood samples from 10 healthy individuals (107 copies of gDNA each). This is inconsistent, at least at an analytical sensitivity of 10−7, with the hypotheses of (a) hypermutation or (b) strong selection of these growth factor-mutated cells during normal lung development leads to accumulation of pre-neoplastic cells with these EGFR mutations, which sometimes can lead to lung cancer in late adulthood. Moreover, MAP was used for large scale, high throughput “gene pool” analysis. No germline or early embryonic somatic mosaic mutation was detected (at a frequency of >0.3%) for the 15/18 bp EGFR deletion mutations in 6,400 individuals, suggesting that early embryonic EGFR somatic mutation is very rare, inconsistent with hypermutation or strong selection of these deletions in the embryo. 2) The second illustration of MAP utility is in personalized monitoring of therapy and early recurrence in cancer. Tumor-specific p53 mutations identified at diagnosis in the plasma of six patients with stage II and III breast cancer were undetectable after therapy in four women, consistent with clinical remission, and continued to be detected after treatment in two others, reflecting tumor progression. Conclusions MAP has an analytical selectivity of one part per billion for detection of MIDIs and an analytical sensitivity of one molecule. MAP provides a general tool for monitoring ultra-rare mutations in tissues and blood. As an example, we show that the personalized cancer signature in six out of six patients with non-metastatic breast cancer can be detected and that levels over time are correlated with the clinical course of disease.

PAP: Detection of Ultra Rare Mutations Depends on P* Oligonucleotides: “sleeping Beauties” Awakened by the Kiss of Pyrophosphorolysis

Detection of Ultra Rare Somatic Mutations in the P53 Gene by Bi-PAP-A, a Tool for Detection of Minimal Residual Disease in Solid Tumors

Selective Enrichment of Low‐Abundance DNA Variants Based on Programmable Peptide Nucleic Acid Probes

Nuclease-Assisted Minor Allele Enrichment Using Overlapping Probes-Assisted Amplification-Refractory Mutation System: An Approach for the Improvement of Amplification-Refractory Mutation System-Polymerase Chain Reaction Specificity in Liquid Biopsies

A novel one cycle allele specific primer extension--molecular beacon displacement method for DNA point mutation detection with improved specificity.

Mismatch-Guided Deoxyribonucleic Acid Assembly Enables Ultrasensitive and Multiplex Detection of Low-Allele-Fraction Variants in Clinical Samples

Modified Proofreading PCR for Detection of Point Mutations, Insertions and Deletions Using a Ddntp-Blocked Primer.

Single-step, High-Specificity Detection of Single Nucleotide Mutation by Primer-Activatable Loop-Mediated Isothermal Amplification (PA-LAMP).

Multiplexed Detection of Mutant Circulating Tumor DNA Using Peptide Nucleic Acid Clamping Asymmetric Polymerase Chain Reaction and Liquidchip.

Programmable One-Pot Enzymatic Reaction for Direct Fluorescence Detection of Ultralow-Abundance Mutations in the DNA Duplex

Argonaute Integrated Single-Tube PCR System Enables Supersensitive Detection of Rare Mutations

High-Fidelity and Simultaneous Sensing of Endogenous Mutant and Wild p53 Proteins for Precise Cancer Diagnosis and Drug Screening

Phosphoramidate Azole Oligonucleotides for Single Nucleotide Polymorphism Detection by PCR

On-chip Oligonucleotide Ligation Assay Using One-Dimensional Microfluidic Beads Array for the Detection of Low-Abundant DNA Point Mutations

Temperature-boosted PAM-less activation of CRISPR-Cas12a combined with selective inhibitors enhances detection of SNVs with VAFs below 0.01%

Other Transgenic Mutation Assays: APRT: A Versatile in Vivo Resident Reporter of Local Mutation and Loss of Heterozygosity

Magnetic beads based rolling circle amplification-electrochemiluminescence assay for highly sensitive detection of point mutation.

Tweezer PCR: A Highly Specific Method for Accurate Identification of Low-Abundance Mutations

New Molecular Beacon for P53 Gene Point Mutation and Significant Potential in Serving As the Polymerization Primer.

Analysis of Cancer Mutation Signatures in Blood by A Novel Ultra-Sensitive Assay: Monitoring of Therapy or Recurrence in Non-Metastatic Breast Cancer

All-in-one approaches for rapid and highly specific quantifcation of single nucleotide polymorphisms based on ligase detection reaction using molecular beacons as turn-on probes